Core Viewpoint - The expiration of the core patent for Semaglutide on March 20 marks the beginning of a new phase for the GLP-1 industry in China, shifting the focus from legal barriers to market competition and commercialization strategies [2][3]. Group 1: Market Dynamics - The expiration of the patent does not guarantee the immediate availability of generic drugs; the actual competition will depend on regulatory approval, production capabilities, commercialization speed, and pricing strategies [3]. - Currently, ten domestic companies are in the application stage for Semaglutide, indicating a collective race rather than a single breakthrough [5]. - The competition will not solely be based on pricing but will also involve consistency, supply stability, channel capabilities, and the speed of advancing indications [5]. Group 2: Approval Timeline - The companies most likely to receive approval first for diabetes indications are Jiuyuan Gene and Lizhu Group, with Jiuyuan being the first to submit its application [6]. - Jiuyuan's application for diabetes indication was accepted on April 2, 2024, while Lizhu's application was accepted on June 13, 2024 [6]. - The market expects the first diabetes indication approvals to be granted by the second half of 2026, while weight management indications may not see significant approvals until after 2027 [8]. Group 3: Pricing Strategies - A price war is anticipated, with the original drug already showing price reductions, indicating a preemptive price defense strategy in the GLP-1 market [9]. - The diabetes indication is expected to enter a more intense price competition phase post-approval, while the weight management indication may not see drastic price drops initially due to brand and consumer factors [9]. - The overall trend suggests that Semaglutide will not maintain its previous high-price, scarce, and strong brand premium status in the Chinese market [9].

Core Insights - The core focus of the article is the impending expiration of the core molecular patent for Novo Nordisk's GLP-1 drug, semaglutide, in China, which is leading to a surge in local generic versions being approved [3][6]. Group 1: Market Dynamics - A significant number of Chinese pharmaceutical companies, including Jiuyuan Gene, Livzon Pharmaceutical, East China Pharmaceutical, Qilu Pharmaceutical, and Zhengda Tianqing, are preparing to launch their generic versions of semaglutide, with over ten companies expected to enter the market soon [3][6]. - Jiuyuan Gene's biosimilar, Jikeqin, has received formal acceptance for its market application from the National Medical Products Administration of China, targeting weight management for obese or overweight individuals [3][6]. - An endocrinologist indicated that the market will soon experience a "bargain price" era for weight loss drugs as more generics become available, following significant price reductions for Novo Nordisk's semaglutide and Eli Lilly's tirzepatide after they were included in medical insurance [3][6]. Group 2: Competitive Landscape - Novo Nordisk's stock has seen a decline of over 20% in the past five trading days and more than 44% over the last month, with its market capitalization dropping to below $130 billion, losing approximately $35 billion in value this week [4][7]. - The Chinese market is crucial for Novo Nordisk, being one of the largest markets for weight loss drugs globally, but it is facing intense competition, particularly from the rise of e-commerce platforms that are becoming key sales channels for consumer-oriented medications [4][7]. - A report from Jefferies forecasts that by 2025, sales of semaglutide on Alibaba's Tmall and JD.com platforms will reach approximately 260 million yuan, while local competitor Innovent Biologics' weight loss drug, Ma Shidu, is expected to exceed 400 million yuan in sales [4][7].

Group 1 - The core point of the article highlights the impending expiration of the core molecular patent for Novo Nordisk's GLP-1 drug semaglutide in China, leading to a surge of local generic versions being approved [2] - Jiuyuan Gene's biosimilar drug Jikeqin has received formal acceptance for its market application from the National Medical Products Administration of China, targeting weight management for obese or overweight individuals [2] - More than ten local pharmaceutical companies, including Jiuyuan Gene, Lijuzhong, Huadong Medicine, Qilu Pharmaceutical, and Zhengda Tianqing, are expected to launch their semaglutide generics soon, with over ten more in phase III clinical trials, indicating an upcoming price war [2] Group 2 - Novo Nordisk's stock has dropped over 20% in the past five trading days and more than 44% in the last month, with a market value now below $130 billion, losing approximately $35 billion in market capitalization this week [3] - The Chinese market is crucial for Novo Nordisk, being the largest market for weight loss drugs outside the U.S., but it faces intense competition, particularly from rising e-commerce platforms that are becoming key sales channels for consumer-oriented drugs [3] - A report from Jefferies predicts that by 2025, sales of semaglutide on Alibaba's Tmall and JD platforms will reach 260 million RMB, while local competitor Innovent Biologics' weight loss drug will exceed 400 million RMB in sales [3]

Core Insights - The core patent for Novo Nordisk's GLP-1 drug Semaglutide is set to expire in March, leading to a surge of local Chinese generic versions being approved [1] - Jiuyuan Gene's biosimilar application for Semaglutide has been accepted by the National Medical Products Administration of China, targeting weight management for obese or overweight individuals [1] - A price war is anticipated as over ten local pharmaceutical companies, including Jiuyuan Gene, are preparing to launch their Semaglutide generics, with many others in Phase III clinical trials [1] Company Insights - Novo Nordisk's stock has dropped over 20% in the past five trading days and more than 44% in the last month, with a market capitalization now below $130 billion, losing approximately $35 billion in value this week [2] - The Chinese market is crucial for Novo Nordisk, being the largest market for weight loss drugs outside the U.S., but it faces intense competition from local firms and e-commerce platforms [2] - Local competitors are expected to outperform Novo Nordisk in e-commerce sales, with projections indicating that sales for local competitor Innovent Biologics' weight loss drug will exceed $4 million on platforms like Alibaba's Tmall and JD.com by 2025, compared to Novo Nordisk's expected sales of $2.6 million [2]

Core Viewpoint - Jiuyuan Gene (02566) has announced that the listing application for its product, Jikeqin, has been accepted by the National Medical Products Administration of China, marking a significant step in the development of its long-acting GLP-1 receptor agonist, semaglutide biosimilar [1] Group 1: Product Development - Jikeqin is developed as a biosimilar of semaglutide, classified under biological drug registration category 3.3, intended for weight management in obese or overweight populations [1] - The product mimics the physiological effects of endogenous GLP-1 hormone, promoting insulin secretion, inhibiting glucagon release, suppressing appetite, and delaying gastric emptying to improve blood sugar control and facilitate weight management [1] Group 2: Clinical Trials - Phase III clinical trials have been conducted with Jikeqin in obese subjects, featuring a randomized, open-label, positive control, parallel design to assess clinical equivalence [1] - Results from the trials indicate that Jikeqin demonstrates clinical equivalence to the reference drug in terms of primary efficacy indicators (weight change rate after 44 weeks of treatment) and safety, showcasing good efficacy and tolerability [1] Group 3: Regulatory Milestones - The company received the drug clinical trial approval notice from the National Medical Products Administration in January 2024 and completed the enrollment of all subjects for the Phase III clinical study by December 2024 [1] - The application for market listing has been submitted to the National Drug Review Center for evaluation [1]